Axsome Therapeutics (AXSM) Return on Invested Capital (2023 - 2026)

Axsome Therapeutics has disclosed Return on Invested Capital across 4 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Invested Capital for Q1 2026 came in at 0.0%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (up 1.0% YoY), and the FY2025 annual result was 0.0%, up 1.0% from the prior year.
• Return on Invested Capital came in at 0.0% for Q1 2026 at Axsome Therapeutics, down from 0.0% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q4 2025 to a low of 0.01% in Q4 2024.
• The 4-year median for Return on Invested Capital is 0.01% (2024), against an average of 0.01%.
• Across the five-year window, Return on Invested Capital fell 1 bps in 2024 and grew 1 bps in 2025, its largest moves.
• Axsome Therapeutics' Return on Invested Capital stood at 0.01% in 2023, then plunged by 141 bps to 0.01% in 2024, then jumped by 86 bps to 0.0% in 2025, then plunged by 71 bps to 0.0% in 2026.
• The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.